Indian Journal of Hematology and Blood Transfusion最新文献

{"title":"Prognostic Factors and Outcomes of Early-Stage Hodgkin's Lymphoma: Multi-Institutional Data From South India.","authors":"Lakshmi Sandhya Singuluri, Perumal Kalaiyarasi Jayachandran, Luxitaa Goenka, Praveen Kumar Shenoy, Krishna Kumar Rathnam, Arun Seshachalam, Nikita Mehra, Mummoorthy Ram Kumar, Murugan Mangai Suseela, Vineetha Raghavan, Chandran K Nair, Biswajit Dubashi, Manikandan Dhanushkodi, Prasanth Ganesan","doi":"10.1007/s12288-023-01692-9","DOIUrl":"10.1007/s12288-023-01692-9","url":null,"abstract":"<p><p>Early-stage Hodgkin's lymphoma (ESHL) is highly curable, usually with a combination of chemotherapy and radiation. Real-world data may show differences in survival and prognostic factors when compared to clinical trials. There is limited published literature on ESHL from India. The data on the baseline characters, treatment, and outcomes of patients with ESHL (stage IA, IB, and IIA) were obtained from five institutions' medical records and entered in a common database. Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan Meier method, and cox-regression analysis was used to identify prognostic factors. There were 258 patients [median age was 37 (18-75) years; [males:160 (62%); stage I: 41%; B symptoms: 17 (6%); bulky disease:19 (15%)] treated between 2000 and 2020 who were evaluable. The common chemotherapies used were ABVD [N = 180 (70%)], COPP-ABVD hybrid [N = 52 (21%)], and COPP [N = 14 (5%)]. Median number of cycles were 4 (2-8) and 93 (47%) received radiation at end of treatment. After a median follow-up of 60 months, the 5 years EFS was 87% and OS was 92%. On multivariate analysis, the following factors adversely affected the EFS: Male gender [hazard ratio (HR) = 2.23, <i>P</i> = 0.02] and Hemoglobin < 10.5g/dL [hazard ration (HR) = 2.20, <i>P</i> = 0.02], and the following adversely affected the OS: Hemoglobin < 10.5g/dL [hazard ratio (HR) = 4.05, <i>P</i> = 0.001], Male gender [hazard ratio (HR) = 3.59, <i>P</i> = 0.004], Stage 2 [hazard ratio (HR) = 2.65, <i>P</i> = 0.002] and ECOG PS (2-3) [hazard ratio (HR) = 3.35, <i>P</i> = 0.01]. Using the hemoglobin, stage and gender a 3-item prognostic score could identify patients with very good outcomes (score 0; 5 years OS:100%) and poor outcomes (score 3; 5 years OS; 49%). This is one of the first multi-center real-world data exclusively focusing on ESHL from India. Though the survival of the entire population was good, there are subsets of patients who have poor outcomes, which may be identified using simple parameters. These parameters need validation in a larger dataset.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12288-023-01692-9.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45989485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporaneous Illustration of Megakaryopoiesis.","authors":"Nishit Gupta, Tina Dadu, Aditi Mittal, Anil Handoo","doi":"10.1007/s12288-023-01674-x","DOIUrl":"10.1007/s12288-023-01674-x","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47178666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single Centre Experience of Effective Desensitization Strategy for Children with High Anti-HLA Donor-Specific Antibodies Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.","authors":"Vimal Kumar, Rishab Bharadwaj, Deepti Sachan, Deenadayalan Munirathnam","doi":"10.1007/s12288-023-01661-2","DOIUrl":"10.1007/s12288-023-01661-2","url":null,"abstract":"<p><p>To assess the incidence of anti-HLA donor-specific antibodies and the effectiveness of desensitization strategy in children who underwent haploidentical HSCT at our hospital. A retrospective review, management and outcomes of children with positive anti-HLA DSA who underwent haploidentical HSCT at our hospital from 2020 to 2022. Three patients with Thalassemia major were treated with 2 cycles of pretransplant immune suppression (PTIS) comprising Fludarabine and Dexamethasone in addition to desensitization. Five out of the 26 children who underwent haploidentical HSCT had positive anti-HLA DSA. Post desensitization, three out of the 5 children engrafted with sustained full donor chimerism, 1 patient developed primary graft rejection, while 1 patient died. It is feasible to desensitize children with high anti-HLA donor specific antibodies undergoing haploidentical HSCT to improve outcomes.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48699716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Severity of Direct Antiglobulin Test Negative ABO Hemolytic Disease of Newborn: A Retrospective Analysis at a Tertiary Children's Hospital.","authors":"Huimin Ma, Zhe Sheng, Jin Xu","doi":"10.1007/s12288-023-01689-4","DOIUrl":"10.1007/s12288-023-01689-4","url":null,"abstract":"<p><p>This study aimed to evaluate the severity of ABO hemolytic disease of newborn (ABO-HDN) with negative direct antiglobulin test (DAT), which was identified by elution test. We retrospectively reviewed the clinical records of all neonates admitted with the diagnosis of neonatal hyperbilirubinemia requiring phototherapy or exchange transfusion. Neonates were divided into four groups according to their immunohematology test results. Then their essential laboratory results, magnetic resonance image (MRI), brainstem auditory evoked potential (BAEP) findings, and rate of exchange transfusion were compared between different groups. We found that neonates in ABO-HDN with negative DAT group developed jaundice faster and anaemia more severely than those in the non-HDN group. Although they might get less severe anaemia than neonates in ABO-HDN with positive DAT group and the Rh-HDN group, neonates in ABO HDN with negative DAT group might develop jaundice as quickly as the latter two groups. As to MRI and BAEP findings, there were no significant differences among the four groups. The rate of exchange transfusion in ABO-HDN with negative DAT group was higher than that in the non-HDN group but lower than that in ABO-HDN with positive DAT group, though without statistical significance. It suggested that in the presence of clinical suspicion of ABO-HDN with negative DAT result, the elution test should be added to rule out or confirm the diagnosis to help prevent the morbidity from hyperbilirubinemia.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42597866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Evaluation of Performance of Sysmex XN 3000 and Horiba Yumizen H2500 Automated Complete Blood Count Analysers.","authors":"Rajesh Kumar Bhola, Christophe Fudaly, Shubham Rastogi","doi":"10.1007/s12288-023-01687-6","DOIUrl":"10.1007/s12288-023-01687-6","url":null,"abstract":"<p><p>Modern automated laboratory haematology analysers use various methods to measure different haematological parameters. These parameters are useful in the diagnostic and clinical interpretation of patient symptoms. So, it is very important to compare the performance of different analysers measuring the same parameter. Hence, a comparison of complete blood counts analysed by Sysmex XN 3000 and Horiba Yumizen H2500 was performed. Total 296 EDTA anti-coagulated blood samples were processed in both the analysers in duplicate within 4 h of collection. The white blood cell count, red blood cell count, erythrocyte indices, differential leukocyte count, platelet count and platelet indices and reticulocyte count were compared. A good level of correlation and agreement between different parameters were obtained. A strong correlation was observed (r > 0.9) between Sysmex XN 3000 and Yumizen H2500 for WBC (0.997), RBC (0.997), Haemoglobin (0.999), haematocrit (0.974), MCV (0.902), MCH (0.99),, platelet count by impedance (0.989), mean platelet volume (0.954), plateletcrit (0.971), platelet distribution width (PDW) (0.916), neutrophils (0.997), lymphocytes (0.989), monocytes (0.943), and eosinophils (0.991) counts. A moderate correlation was observed for RDW-CV (0.75). The basophils count showed poor correlation (r < 0.5) possibly because of sample selection with mostly low basophils count. An acceptable bias was observed for most of the parameters like WBC, RBC, Haemoglobin, Haematocrit, platelet counts, neutrophils, lymphocytes, eosinophils and monocytes. The studied instruments ensured satisfactory interchangeability except for few parameters, thus facilitate substitution of one analyser by another without affecting the clinical decision making.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43185194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS.","authors":"Ömer Atmış, Nalan Neşe, İsmet Aydoğdu, İlknur Alaca, Hanife Seda Mavili, Aydın İşisağ","doi":"10.1007/s12288-023-01667-w","DOIUrl":"10.1007/s12288-023-01667-w","url":null,"abstract":"<p><p>It is aimed to determine expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), CD163 and CD14 in diffuse large B-cell lymphomas (DLBCL), and whether these markers may predict prognosis in DLBCL cases. A total of 52 nodal DLBCL, NOS cases with no known extranodal involvement at the time of diagnosis were evaluated. PD-1, PD-L1, CD163, and CD14 were studied by immunohistochemistry. The relationships between the results and clinical and laboratory prognostic markers were investigated. It was observed that patients with PD-1 expression < 5 positive cells/HPF had worse overall survival. No significant relationship was found between survival and PD-L1, CD163 and CD14 expressions. In addition, cases that are > 60 years of age, that have Eastern Cooperative Oncology Group (ECOG) performance score ≥ 2, stage IV disease, high International Prognostic Index score score (≥ 3), elevation of LDH, low albumin level, low hemoglobin level, low peripheral blood lymphocyte count, high peripheral blood neutrophil/lymphocyte ratio, high peripheral blood platelet/lymphocyte ratio were found to have worse overall survival. It was concluded that in patients with low number of PD-1 positive tumor-infiltrating lymphocytes have low survival rates and therefore PD-1 expression may be useful in indicating prognosis.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48860984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasminogen Activator Inhibitor-1 4G/5G Promoter Polymorphism in Indian Patients with Deep Vein Thrombosis.","authors":"Saniya Sharma, Manu Jamwal, Varun Uppal, Hari Kishan Senee, Manav Jindal, Jasmina Ahluwalia, Reena Das, Neelam Varma, Pankaj Malhotra, Narender Kumar","doi":"10.1007/s12288-023-01660-3","DOIUrl":"10.1007/s12288-023-01660-3","url":null,"abstract":"<p><p>A single guanosine deletion/insertion (4G/5G) polymorphism in the promoter region of plasminogen activator inhibitor-1 (<i>PAI-1</i>) gene encoding PAI-1 protein has been investigated in deep vein thrombosis (DVT) patients. The association between <i>PAI-1 4G/5G</i> polymorphism and increased risk of DVT has been reported in some studies, while others have reported a lack of association. The present study aimed to investigate if the <i>PAI-1</i> 4G/5G polymorphism is associated with an increased risk of DVT in the Indian population and to assess its association with thrombophilic risk factors. Fifty-two adult patients with a history of chronic or recurrent DVT and 52 healthy adult controls were genotyped for <i>PAI-1</i> 4G/5G polymorphism. Plasma levels of PAI-1 and other thrombophilic risk factors were also measured. <i>PAI-1</i> 4G/5G polymorphism was not significantly associated with an increased risk of DVT. Protein C deficiency was significantly associated with the 4G/4G genotype. Patients with the 4G/4G genotype had significantly reduced PAI-1 levels as compared to the controls. <i>PAI-1</i> 4G/5G polymorphism did not significantly contribute to an increased risk of DVT in the Indian population. However, in the presence of thrombophilic risk factor abnormalities, the risk of DVT is increased in individuals with the 4G/4G genotype in the Indian cohort.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12288-023-01660-3.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42129378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study.","authors":"Charanpreet Singh, Aditya Jandial, Arihant Jain, Deepesh Lad, Alka Khadwal, Rajender Basher, Amanjit Bal, Pankaj Malhotra, Gaurav Prakash","doi":"10.1007/s12288-023-01693-8","DOIUrl":"10.1007/s12288-023-01693-8","url":null,"abstract":"<p><p>Standard therapy for patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) involves salvage chemotherapy followed by autologous hematopoietic stem cell transplant. However, information regarding the number of patients receiving salvage therapy and associated factors is not available from low/middle income countries (LMICs). All patients treated at our center with RR DLBCL from 2016 to 2021 were included in the study. Univariate and multivariate analyses was performed to find factors associated with the lack of receipt of salvage chemotherapy. Eighty-five patients were included in the study. Most patients had primary refractory disease (69.4%). Only 26 patients received standard salvage therapy, while the others (N = 59) received metronomic/palliative oral therapy. On univariate analysis, patients with an annual income below India's Gross National Income per capita (<i>p</i> = 0.014), an education level below Class XII (<i>p</i> = 0.025), Stage III/IV disease at relapse (<i>p</i> = 0.018) and CNS relapse (<i>p</i> = 0.027) were more likely to receive palliative therapy. Conversely, patients with a late relapse were more likely to receive salvage therapy (<i>p</i> = 0.001). On multivariate analysis, patients with Stage III/IV relapse (<i>p</i> = 0.030) and an education level less than Class XII (<i>p</i> = 0.012) were more likely to receive palliative therapy, while patients with a late relapse (<i>p</i> = 0.001) were more likely to receive salvage therapy. Patients who received salvage therapy had a longer Median OS than those who received palliative therapy (<i>p</i> < 0.001). Timing of relapse, stage at relapse and educational status of the patient are significant factors affecting access to effective therapy for patients with RR DLBCL in LMICs.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47875389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Hematopoietic Stem Cell Transplantation in a Child with Thalassemia major and Moderate Haemophilia A","authors":"Debranjani Chattopadhyay, A. Abraham, Biju George","doi":"10.1007/s12288-024-01751-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01751-9","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140216746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Myeloid Leukemia t (8;21) with Masked Systemic Mastocytosis","authors":"M. B. Deepak, S. Bharath Ram, S. Chougule, Hema Subramanian, K. S. Shalini, S. Damodar","doi":"10.1007/s12288-024-01733-x","DOIUrl":"https://doi.org/10.1007/s12288-024-01733-x","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139807380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}